[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Melanocortin Receptor 4 - Pipeline Review, H1 2020

April 2020 | 83 pages | ID: M130E07175B6EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Melanocortin Receptor 4 - Pipeline Review, H1 2020

SUMMARY

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 1 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Metabolic Disorders, Genetic Disorders, Musculoskeletal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Immunology which include indications Obesity, Type 2 Diabetes, Cachexia, Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis, Prader-Willi Syndrome (PWS), Rheumatoid Arthritis and Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome).

The latest report Melanocortin Receptor 4 - Pipeline Review, H1 2020, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
  • The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
Aequus BioPharma Inc
Eton Pharmaceuticals Inc
Mallinckrodt Plc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
(liraglutide + setmelanotide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy
Mar 30, 2020: Rhythm Pharmaceuticals completes rolling submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR deficiency obesities
Mar 18, 2020: Rhythm Pharmaceuticals receives orphan drug designation from U.S. FDA for Setmelanotide for the treatment of Alstrom Syndrome
Mar 16, 2020: Mallinckrodt confirms court decision in lawsuit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and provides update related to global opioid settlement and present financing activities
Mar 05, 2020: Data on Acthar Gel (repository corticotropin injection) therapy in immunoglobulin a nephropathy (IgAN) published in Kidney International Reports
Mar 04, 2020: Mallinckrodt announces publication of new data on Acthar Gel (Repository Corticotropin Injection) in rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis published in Open Access Rheumatology: Research and Reviews
Feb 27, 2020: Mallinckrodt to present new data from two studies on Acthar Gel (Repository Corticotropin Injection) therapy in Multiple Sclerosis (MS) relapse at Fifth Annual ACTRIMS Forum 2020
Jan 06, 2020: Rhythm Pharmaceuticals announces leadership transition
Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis
Dec 05, 2019: Rhythm Pharmaceuticals completes enrollment of pivotal cohort in phase 3 clinical trial evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes
Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease
Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population
Nov 04, 2019: Rhythm Pharmaceuticals announces late-breaking data from phase 3 trials of Setmelanotide in POMC and LEPR deficiency obesities at ObesityWeek 2019
Oct 30, 2019: Rhythm Pharmaceuticals announces late-breaking data presentations at ObesityWeek 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aequus BioPharma Inc, H1 2020
Pipeline by Eton Pharmaceuticals Inc, H1 2020
Pipeline by Mallinckrodt Plc, H1 2020
Pipeline by Palatin Technologies Inc, H1 2020
Pipeline by Rhythm Pharmaceuticals Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aequus BioPharma Inc
Eton Pharmaceuticals Inc
Mallinckrodt Plc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc


More Publications